Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Bullish +73

We're adding to an out-of-favor stock with limited exposure to Iran war upheaval

📈 Jim Cramer's Charitable Trust is acquiring additional shares of Cardinal Health (CAH) at approximately $210 per share.

📊 The new purchase increases total holdings to 475 shares, raising the portfolio weight from around 2.5% to roughly 2.6%.

📉 CAH stock has declined about 9% since the onset of the Iran conflict, which the investment team views as an attractive entry point.

💊 The company generates majority revenue from distributing pharmaceuticals and healthcare products in the U.S., limiting geopolitical exposure.

🚀 EPS growth is forecasted at roughly 25% for the current fiscal year, driven partly by a surge in GLP-1 medication sales.

🏛️ Chairman Gregory Kenny is retiring effective immediately after 17 years on the board, replaced by director Patricia Hemingway Hall.

🔍 Management confirms the leadership change was personal and not due to any operational disagreements with Kenny.

💼 Kenny also resigned from Ingredion's board simultaneously, reinforcing that the departure was unrelated to Cardinal Health specifically.

✅ In an 8-K filing, Cardinal stated it remains confident in its fiscal 2026 outlook despite recent volatility.

📅 The company is scheduled to report its next earnings on April 30 to address investor concerns about potential slowdowns.

Bullish Signals
  • Cardinal Health has pulled back roughly 9% since the start of the conflict with Iran, presenting a buying opportunity with limited exposure to geopolitical tensions.
  • With no real exposure to the war and earnings per share expected to grow roughly 25% in its current fiscal year, investors are encouraged to build up the position into its recent weakness.
  • Sales of GLP-1 medications have been a nice tailwind to its Pharmaceutical and Specialty Solutions business, adding 6 percentage points of revenue growth in the company's most recent quarter.
  • Cardinal Health remains confident in its fiscal 2026 outlook, which helps ease concerns regarding potential sudden earnings slowdowns from leadership changes.
  • The company will report earnings on April 30, providing a near-term catalyst for investors.
Risk Factors
  • The stock has already pulled back roughly 9% since the start of the conflict with Iran, indicating recent weakness.
  • A sudden retirement from board chairman Gregory Kenny, who had been on the board since 2007 and chair since 2018, can be unsettling to investors.
  • While the company expressed confidence in its fiscal 2026 outlook, this follows concerns of a potential sudden earnings slowdown triggered by the leadership change.
  • The article notes that they may have 'jumped the gun too early' on the position, suggesting timing risks were taken before full validation of the investment thesis.
Full Analysis
Jim Cramer's Charitable Trust is increasing its position in Cardinal Health (CAH) by purchasing an additional 25 shares at approximately $210 per share. This trade follows Wednesday's market activity, raising the trust's total holdings to 475 shares and adjusting the stock's weighting from around 2.5% to roughly 2.6%. The investment thesis centers on Cardinal Health being an out-of-favor stock with minimal exposure to geopolitical risks, specifically noting that the company makes most of its revenue distributing branded and generic pharmaceuticals, specialty drugs, and over-the-counter consumer products in the United States. Consequently, the trust believes the stock has oversold itself, having dropped about 9% since the onset of the Iran conflict, which limits meaningful upside impact from that macro trend. Beyond geopolitical stability, Cardinal Health is supported by strong growth fundamentals, particularly in its Pharmaceutical and Specialty Solutions business. Sales of GLP-1 medications have provided a significant tailwind, contributing an additional 6 percentage points to revenue growth in the most recent quarter. With earnings per share expected to increase roughly 25% in the current fiscal year, the trust views the recent price weakness as an opportunity to build the position. The company recently announced that Gregory Kenny, who joined the board in 2007 and became chairman in 2018, is retiring effective immediately to be replaced by director Patricia Hemingway Hall. While sudden board changes can unsettle investors, Cardinal stated this decision was not tied to disagreements over operations or policies, and Kenny's simultaneous resignation from Ingredion suggests a personal reason for his departure. Despite the leadership transition, Cardinal Health reaffirmed its confidence in its fiscal 2026 outlook in an 8-K filing, aiming to ease investor concerns regarding a potential earnings slowdown following Kenny's exit. The company is scheduled to report earnings on April 30. As a subscriber to the CNBC Investing Club with Jim Cramer, members receive trade alerts before Jim executes trades for his charitable trust. Jim adheres to specific timing rules: waiting 45 minutes after a trade alert and 72 hours if he has discussed the stock on CNBC TV before purchasing or selling. The article concludes with standard disclaimers noting that no fiduciary obligation exists between the publisher and the reader, outcomes are not guaranteed, and data provided is subject to terms of use regarding market data delays.